GPCM
LRMR icon

Granite Point Capital Management’s Larimar Therapeutics LRMR Stock Holding History

Granite Point Capital Management’s Portfolio LRMR Stock Details LRMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-111,819
Closed -$358K – 102
2022
Q3 		$358K Buy
+111,819
New +$280K 0.15% 71

Other funds holding LRMR

DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
CA
CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $19.7B AUM 39.39% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.52B AUM 36.54% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Granite Point Capital Management's LRMR Position: Q4 2022 in Review

Granite Point Capital Management sold out of Larimar Therapeutics (LRMR) in Q4 2022, closing a stake of 111,819 shares — an estimated $358K sold.

Granite Point Capital Management first reported a position in LRMR in Q3 2022 and held it in 1 quarter. The position peaked at $358K in Q3 2022. 48 funds tracked by Wall St. Rank hold LRMR as of Q4 2022.

  • Granite Point Capital Management reported no remaining Larimar Therapeutics position as of Q4 2022 after selling out during the quarter.
  • Granite Point Capital Management sold 111,819 Larimar Therapeutics shares in Q4 2022, an estimated $358K.
  • Granite Point Capital Management first reported a position in Larimar Therapeutics in Q3 2022 and held it in 1 quarter.
  • Granite Point Capital Management's Larimar Therapeutics position peaked at $358K in Q3 2022.
  • 48 funds tracked by Wall St. Rank held Larimar Therapeutics as of Q4 2022.

Based on Granite Point Capital Management's 13F filing for Q4 2022, filed 7 Feb 2023.